|1.||Borgström, Anders: 4 articles (01/2009 - 04/2002)|
|2.||Borgström, A: 4 articles (01/2008 - 01/2000)|
|3.||Appelros, S: 4 articles (01/2008 - 02/2001)|
|4.||Regnér, S: 2 articles (01/2008 - 01/2008)|
|5.||Hjalmarsson, C: 2 articles (01/2008 - 01/2008)|
|6.||Sadic, J: 2 articles (01/2008 - 01/2008)|
|7.||Manjer, J: 2 articles (01/2008 - 01/2008)|
|8.||Appelros, Stefan: 2 articles (01/2003 - 04/2002)|
|9.||Uhl, W: 2 articles (08/2002 - 01/2000)|
|10.||Büchler, M W: 2 articles (08/2002 - 01/2000)|
02/01/2001 - "Measurement of CAPAP in urine may be of value in the management of individual patients with pancreatitis and in the selection of patients for therapeutic trials."
09/01/2000 - "The serum carboxypeptidase B activation peptide concentrations of patients with severe acute pancreatitis were significantly higher than those of patients with mild acute pancreatitis on the 2(nd) (P=0.044) and 3(rd) days (P=0.028) of the study. "
07/01/2015 - "Both serum and urinary CAPAP have the potential to act as a stratification marker on admission in predicting severity of acute pancreatitis."
07/01/2015 - "At the time of admission, the AUC of serum CAPAP for predicting severity of acute pancreatitis was 0.86 with pooled sensitivity, specificity and DOR of 0.90, 0.70 and 19.08, respectively. "
07/01/2015 - "Prediction of the severity of acute pancreatitis on admission by carboxypeptidase-B activation peptide: A systematic review and meta-analysis."
01/01/2006 - "The rise in CRP was without a commensurate rise in CAPAP or outcome measures so there was no evidence that this represented pancreatic necrosis. "
08/01/2002 - "Immunoreactive carboxypeptidase B activation peptide (ir-CAPAP) concentration in serum on admission was 0.7 nmol/l (0-18.1) in patients with oedematous pancreatitis compared with 5.8 nmol/l (1.9-34) in patients with later development of pancreatic necrosis. "
04/01/2002 - "We sought clues from circulating trypsinogen load at admission as marker of initial acinar injury, trypsinogen activation using the carboxypeptidase B activation peptide as surrogate, proteinase inhibitors, the coagulation-fibrinolysis axis, indicators of inflammation, oxidative stress markers, and antioxidant status. "
01/01/2008 - "The pathophysiology of acute pancreatitis (AP) may be studied using markers of protease activation (active carboxypeptidase B (aCAP), the activation peptide of carboxypeptidase B (CAPAP)), leakage of pancreatic enzymes (trypsinogen-2, procarboxypeptidase B (proCAP), amylase), and inflammation (monocyte chemoattractant protein-1 (MCP-1), CRP). "
|4.||Systemic Inflammatory Response Syndrome (Sepsis Syndrome)
01/01/2000 - "There are a variety of mediators of the "systemic inflammatory response syndrome" which are elevated in this disease (C-reactive protein, antiproteases, enzyme activation peptides like trypsinogen activation peptide (TAP) and carboxypeptidase B activation peptide (CAPAP), PMN-elastase, complement factors, chemokines and interleukins and others). "
|5.||Abdominal Pain (Pain, Abdominal)
|1.||carboxypeptidase B activation peptide
|4.||trypsinogen activation peptide
|5.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|9.||Leukocyte Elastase (Neutrophil Elastase)